Tissue-based long non-coding RNAs “PVT1, TUG1 and MEG3” signature predicts Cisplatin resistance in ovarian Cancer
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | El-Khazragy, Nashwa | |
| dc.contributor.author | Mohammed, Hayam Fathy | |
| dc.contributor.author | Yassin, Mohamed | |
| dc.contributor.author | Elghoneimy, K.K. | |
| dc.contributor.author | Bayoumy, Walid | |
| dc.contributor.author | Hewety, Amr | |
| dc.contributor.author | EL Magdoub, Hekmat M. | |
| dc.contributor.author | Elayat, Wael | |
| dc.contributor.author | Zaki, Walid | |
| dc.contributor.author | Safwat, Gehan | |
| dc.contributor.author | Mosa, Mai | |
| dc.contributor.author | Zedan, Khouloud | |
| dc.contributor.author | Salem, Salema | |
| dc.contributor.author | Bannunah, Azzah M. | |
| dc.contributor.author | Mansy, Azza | |
| dc.date.accessioned | 2020-08-12T12:36:35Z | |
| dc.date.available | 2020-08-12T12:36:35Z | |
| dc.date.issued | 2020-08 | |
| dc.description.abstract | Objectives: The current study aimed to investigate the potentiality of three lncRNAs “Plasmacytoma variant translocation 1(lnc-PVT1), Taurine upregulated gene type 1(lnc- TUG1) and Maternally expressed gene 3 (lnc-MEG-3)”, to predict Cisplatin resistance in ovarian cancer (OC), in addition, to access their prognostic significance. Methods: The expression level of lncRNAs were measured in 100 formalin-fixed paraffin- embedded tissue (FFET) samples of OC patients who were treated by Cisplatin-based chemotherapy using qPCR.Results: The results showed that lnc_PVT1 was significantly higher by 2.3 folds in Cisplatin resistant tissues, while, lnc-TUG1 and lnc-MEG3 were downregulated by 1.2 and 3 folds, respectively. In addition, the three lncRNAs exhibited high sensitivity and specificity in predicting chemo-resistance and they were negatively associated with OS and progression- free survival (p<0.001). Conclusion: The lnc-PVT1, lnc-TUG1, and lnc-MEG3 transcriptome signatures could be used for predicting resistance to Cisplatin in OC patients. | en_US |
| dc.identifier.doi | https://doi.org/10.1016/j.ygeno.2020.08.005 | |
| dc.identifier.other | https://doi.org/10.1016/j.ygeno.2020.08.005 | |
| dc.identifier.uri | https://t.ly/9kLR | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Elsevier Inc.Mansy | en_US |
| dc.relation.ispartofseries | Genomics;S0888-7543(20)30846-6 | |
| dc.subject | lnc- MEG3. | en_US |
| dc.subject | lnc-TUG1 | en_US |
| dc.subject | lnc-PVT1 | en_US |
| dc.subject | Cisplatin resistance | en_US |
| dc.subject | Long non-coding RNA | en_US |
| dc.subject | Ovarian cancer | en_US |
| dc.title | Tissue-based long non-coding RNAs “PVT1, TUG1 and MEG3” signature predicts Cisplatin resistance in ovarian Cancer | en_US |
| dc.type | Article | en_US |